Patients & Caregivers
For Patients & Caregivers
At Aldeyra, we are working to develop safe, effective drugs that improve lives.
Dry Eye Disease & Allergic Conjunctivitis
Dry eye disease and allergic conjunctivitis are common conditions that cause red, burning, inflamed eyes. Aldeyra is developing a new potential treatment that, if approved for sale, could reduce inflammation and help patients avoid steroid use.
Proliferative vitreoretinopathy (PVR) is an eye condition that causes the retina to detach, most commonly after retinal detachment repair surgery or an eye injury. Aldeyra is developing a new potential treatment that, if approved for sale, could be the first FDA-approved drug for preventing PVR.
Early Access Program
Aldeyra is committed to providing patients with access to our therapies. Find out how to request access to our investigational products here.
Check here to learn about the investigational medicines we are developing and see which studies may be recruiting patients to participate in clinical trials.